RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
 Clinical Trials
 Infectious Diseases
  Anti Cancer Drugs
  Anti-Clotting Drugs
  Fatty Acids
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Antivirals Channel

subscribe to Antivirals newsletter
Latest Research : Pharmacology : Antivirals

   EMAIL   |   PRINT
Further Studies Needed for Tipranavir

May 20, 2005 - 8:27:00 AM
"We as a committee have agreed that we feel that there is efficacy demonstrated, but the exact usefulness needs to be monitored in the future," committee chair Janet Englund (University of Washington) said.

[RxPG] Boehringer Ingelheim's Aptivus should be approved for treatment resistant HIV patients, but further studies are needed to guide use of the drug, FDA's Antiviral Drugs Advisory Committee recommended May 19.

"We as a committee have agreed that we feel that there is efficacy demonstrated, but the exact usefulness needs to be monitored in the future," committee chair Janet Englund (University of Washington) said.

The panel voted 11 to 3 in favor of recommending accelerated approval for Aptivus (tipranavir).

Committee members emphasized that further data are necessary to understand how to appropriately use the agent.

The committee needs "guidance both from the company's future studies and from the FDA to be able to use the drug in the best possible way," Englund said.

Further information is needed on how to monitor and manage adverse events, as well as greater clarity on which patients are most likely to respond to tipranavir, committee members said.

Studying long-term liver toxicity should be a priority, committee members said. In pivotal trials, 6% of tipranavir patients exhibited grade 3/4 elevations in ALT/ALS liver enzymes, compared to 2% of patients receiving active control.

"I clearly would urge the pharmaceutical sponsor, since we know that there is this persistent elevation in liver function studies, to generate data that lets us know the baggage with elevation over time," committee member Lauren Wood (Uniformed Services University of Health Sciences) said.

Genotype data on patients likely to respond to Aptivus would also be useful, committee members said. An eight-week "�escape clause" in the Phase III trials made it difficult to isolate which patients responded to therapy.

BI is currently conducting an extended follow-up of the two pivotal trials, as well as trials in treatment-na've HIV patients and pediatric patients.

Publication: FDA's Antiviral Drugs Advisory Committee
On the web: www.fdaadvisorycommitte.com 

Advertise in this space for $10 per month. Contact us today.

Related Antivirals News
Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Complete Inhibition of Viral Replication in H5N1 In Vivo Model by Bavituximab
FDA Gives Tentative Approval to Abacavir
Telbivudine emerging as a potent new treatment option for Hepatitis B
New Saquinavir Formulation Simplifies Dosing Regimen for HIV Patients
CPG 10101 Shows Significant Antiviral Activity in Chronic Hepatitis C Patients
Further Studies Needed for Tipranavir
Comparator Arm Suboptimal in Tipranavir Trial
Telbivudine Demonstrates Advantages Over Lamivudine in HBeAg-positive Chronic Hepatitis B
VX-950 : An Oral Hepatitis C virus Protease Inhibitor Shows Potent Antiviral Activity

Subscribe to Antivirals Newsletter

Enter your email address:

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)